1032650-53-5

Basic information

• Product Name: 4-bromo-2-(bromomethyl)pyridine
• Synonyms: 4-bromo-2-(bromomethyl)pyridine
• CAS NO: 1032650-53-5
• Molecular Formula: C₆H₅Br₂N
• Molecular Weight: 250.9186
• Mol File: 1032650-53-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-bromo-2-(bromomethyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-2-(bromomethyl)pyridine(1032650-53-5)
• EPA Substance Registry System: 4-bromo-2-(bromomethyl)pyridine(1032650-53-5)

Safety Data

• Hazardous Substances Data: 1032650-53-5(Hazardous Substances Data)

Usage

General Description

4-bromo-2-(bromomethyl)pyridine is a chemical compound with the molecular formula C6H5Br2N. It is a versatile building block for the synthesis of various pharmaceuticals and agrochemicals due to its pyridine ring system and bromine functionalities. 4-bromo-2-(bromomethyl)pyridine is commonly used in organic synthesis as a reactant in the production of new chemical entities. It is known to have both a bromide and a bromomethyl group attached to the pyridine ring, making it a useful intermediate in the preparation of complex organic molecules. 4-bromo-2-(bromomethyl)pyridine is a valuable tool in the field of medicinal and agricultural chemistry, and its applications extend to the development of new drugs and pesticides.

Upstream product

• 131747-45-0 4-bromo-2-(hydroxymethyl)pyridine 
• 22282-99-1 4-bromo-2-methylpyridine 

Downstream Products

• 1032650-54-6 N-(4-bromopyridin-2-ylmethyl)-4-fluorobenzamide 

Relevant articles and documents

NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION

The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists

The important roles of the CXCL12/CXCR4 axis in numerous pathogenic pathways involving HIV infection and cancer metastasis make the CXCR4 receptor an attractive target for the development of therapeutic agents. Through scaffold hybridization of a few known CXCR4 antagonists, a series of novel aminopyrimidine derivatives was developed. Compound 3 from this new scaffold demonstrates excellent binding affinity with CXCR4 receptor (IC50 = 54 nM) and inhibits CXCL12 induced cytosolic calcium increase (IC50 = 2.3 nM). Furthermore, compound 3 possesses good physicochemical properties (MW 353, clogP 2.0, PSA 48, pKa 6.7) and exhibits minimal hERG and CYP isozyme (e.g. 3A4, 2D6) inhibition. Collectively, these results strongly support further optimization of this novel scaffold to develop better CXCR4 antagonists.

ANTIMICROBIAL AGENTS

The invention provides methods of treating a bacterial infection in a mammal comprising administering to the mammal a compound of formula I: [formula should be inserted here] wherein A, B, and X have any of the meanings defined in the specification; or a pharmaceutically acceptable salt thereof, as well as novel compounds of formula I and salts thereof and pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof.